Leukemia & Lymphoma, Volume 53, Issue 2 (2012)

Browse this journal
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Leukemia & Lymphoma, Volume 53, Issue 2 (2012)

See all volumes and issues
Vol 65, 2024 Vol 64, 2023 Vol 63, 2022 Vol 62, 2021 Vol 61, 2020 Vol 60, 2019 Vol 59, 2018 Vol 58, 2017 Vol 57, 2016 Vol 56, 2015 Vol 55, 2014 Vol 54, 2013 Volume 53, 2012 Vol 52, 2011 Vol 51, 2010 Vol 50, 2009 Vol 49, 2008 Vol 48, 2007 Vol 47, 2006 Vol 46, 2005 Vol 45, 2004 Vol 44, 2003 Vol 43, 2002 Vol 42, 2001 Vol 41, 2001 Vol 40, 2000-2001 Vol 39, 2000 Vol 38, 2000 Vol 37, 2000 Vol 36, 1999-2000 Vol 35, 1999 Vol 34, 1999 Vol 33, 1999 Vol 32, 1998-1999 Vol 31, 1998 Vol 30, 1998 Vol 29, 1998 Vol 28, 1997-1998 Vol 27, 1997 Vol 26, 1997 Vol 25, 1997 Vol 24, 1996-1997 Vol 23, 1996 Vol 22, 1996 Vol 21, 1996 Vol 20, 1995-1996 Vol 19, 1995 Vol 18, 1995 Vol 17, 1995 Vol 16, 1995 Vol 15, 1995 Vol 16, 1995 Vol 15, 1995 Vol 14, 1994 Vol 13, 1994 Vol 12, 1993-1994 Vol 11, 1993 Vol 10, 1993 Vol 9, 1993 Vol 8, 1992 Vol 7, 1992 Vol 6, 1991-1992 Vol 5, 1991 Vol 4, 1991 Vol 3, 1990-1991 Vol 2, 1990 Vol 1, 1989-1990
Download citations Download PDFs

Commentary on selected articles in this issue

Article Commentary
Modifying the immune system to treat chronic lymphocytic leukemia
Constantine S. Tam & Varsha Gandhi
Pages: 177-178
Published online: 15 Nov 2011
CitationforModifying the immune system to treat chronic lymphocytic leukemia | Full Text | References | PDF (133.9 KB) | Supplemental
  • 592 Views
  • 0 CrossRef citations
  • 0Altmetric
Free Access

Commentary

Article Commentary
Treatment of patients with chronic lymphocytic leukemia with 17p deletion: the saga continues
Januario E. Castro
Pages: 179-180
Published online: 05 Dec 2011
CitationforTreatment of patients with chronic lymphocytic leukemia with 17p deletion: the saga continues | Full Text | References | PDF (130 KB) | Supplemental
  • 713 Views
  • 0 CrossRef citations
  • 0Altmetric
Free Access
Article Commentary
Hepatitis B infection and myeloma in developing countries: therapeutic dilemmas
Deborah Rund
Pages: 181-182
Published online: 25 Nov 2011
CitationforHepatitis B infection and myeloma in developing countries: therapeutic dilemmas | Full Text | References | PDF (131.1 KB) | Supplemental
  • 622 Views
  • 0 CrossRef citations
  • 0Altmetric
Free Access
Article Commentary
Managing light chain deposition disease
Morie A. Gertz
Pages: 183-184
Published online: 05 Dec 2011
CitationforManaging light chain deposition disease | Full Text | References | PDF (132.4 KB) | Supplemental
  • 2047 Views
  • 13 CrossRef citations
  • 0Altmetric
Free Access

Reviews

Review Article
Large B-cell lymphomas with plasmablastic differentiation: a biological and therapeutic challenge
Santiago Montes-Moreno, Carlos Montalbán & Miguel Angel Piris
Pages: 185-194
Published online: 19 Sep 2011
AbstractforLarge B-cell lymphomas with plasmablastic differentiation: a biological and therapeutic challenge | Full Text | References | PDF (752.3 KB) | Supplemental
  • 1726 Views
  • 44 CrossRef citations
  • 0Altmetric

Review Article

Review Article
The role of CD40/CD40L and interferon regulatory factor 4 in Hodgkin lymphoma microenvironment
Donatella Aldinucci, Annunziata Gloghini, Antonio Pinto, Alfonso Colombatti & Antonino Carbone
Pages: 195-201
Published online: 24 Aug 2011
AbstractforThe role of CD40/CD40L and interferon regulatory factor 4 in Hodgkin lymphoma microenvironment | Full Text | References | PDF (977.3 KB) | Supplemental
  • 599 Views
  • 38 CrossRef citations
  • 0Altmetric
Review Article
Genomic stratification of multiple myeloma treated with novel agents
Allan Jiang, Donna Reece & Hong Chang
Pages: 202-207
Published online: 19 Sep 2011
AbstractforGenomic stratification of multiple myeloma treated with novel agents | Full Text | References | PDF (212.4 KB) | Supplemental
  • 620 Views
  • 11 CrossRef citations
  • 0Altmetric
Review Article
Targeting B lymphoma with nanoparticles bearing glycan ligands of CD22
Weihsu C. Chen, Darren S. Sigal, Alan Saven & James C. Paulson
Pages: 208-210
Published online: 24 Aug 2011
AbstractforTargeting B lymphoma with nanoparticles bearing glycan ligands of CD22 | Full Text | References | PDF (289.3 KB) | Supplemental
  • 660 Views
  • 36 CrossRef citations
  • 0Altmetric

Original Articles: Clinical

Article
Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia
Clive S. Zent, Brian J. Smith, Zuhair K. Ballas, James E. Wooldridge, Brian K. Link, Timothy G. Call, Tait D. Shanafelt, Deborah A. Bowen, Neil E. Kay, Thomas E. Witzig & George J. Weiner
Pages: 211-217
Published online: 19 Sep 2011
AbstractforPhase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia | Full Text | References | PDF (362.6 KB) | Supplemental
  • 566 Views
  • 67 CrossRef citations
  • 0Altmetric

Research Article

Article
Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia
Mark C. Lanasa, Patricia H. Davis, Michael Datto, Zhiguo Li, Jon P. Gockerman, Joseph O. Moore, Carlos M. DeCastro, Daphne R. Friedman, Louis F. Diehl, Catherine Rehder, Harry Cook, F. Joseph Daugherty, Karen M. B. Matta, J. Brice Weinberg & David Rizzieri
Pages: 218-224
Published online: 23 Sep 2011
AbstractforPhase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia | Full Text | References | PDF (230.4 KB) | Supplemental
  • 327 Views
  • 10 CrossRef citations
  • 0Altmetric
Article
Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia
John Hornberger, Carolina Reyes, Ashwini Shewade, Susan Lerner, Mark Friedmann, Leona Han, Hialy Gutierrez, Sacha Satram-Hoang & Michael J. Keating
Pages: 225-234
Published online: 19 Sep 2011
AbstractforCost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia | Full Text | References | PDF (332 KB) | Supplemental
  • 1090 Views
  • 23 CrossRef citations
  • 0Altmetric
Article
Unexpectedly high frequency of European parentage in Venezuelan patients with chronic lymphocytic leukemia
Maria-Elena Marquez, Pierre-Antoine Deglesne, Jose Luis Lopez, Osiris Da Costa, Mildred Borrego, Marcos Hernández, Aixa Muller, Florence Ajchenbaum-Cymbalista & Egidio Romano
Pages: 235-241
Published online: 05 Dec 2011
AbstractforUnexpectedly high frequency of European parentage in Venezuelan patients with chronic lymphocytic leukemia | Full Text | References | PDF (271.8 KB) | Supplemental
  • 84 Views
  • 4 CrossRef citations
  • 0Altmetric
Article
Clinical and pathological features of testicular diffuse large B-cell lymphoma: a heterogeneous disease
Marion J. J. Kuper-Hommel, Maryska L. G. Janssen-Heijnen, Gerard Vreugdenhil, Augustinus D. G. Krol, Hanneke C. Kluin-Nelemans, Jan-Willem W. Coebergh & J. Han J. M. van Krieken
Pages: 242-246
Published online: 19 Sep 2011
AbstractforClinical and pathological features of testicular diffuse large B-cell lymphoma: a heterogeneous disease | Full Text | References | PDF (233.4 KB) | Supplemental
  • 299 Views
  • 12 CrossRef citations
  • 0Altmetric
Article
A phase II study of rituximab combined with pirarubicin–cyclophosphamide, vincristine and prednisolone regimen as first-line therapy for patients with indolent B-cell lymphoma
Hisashi Tsurumi, Takeshi Hara, Naoe Goto, Jun-Ichi Kitagawa, Nobuhiro Kanemura, Takeshi Yoshikawa, Senji Kasahara, Hideko Goto, Kenji Fukuno, Toshiki Yamada, Michio Sawada, Masahito Shimizu, Takeshi Takahashi, Tsuyoshi Takami & Hisataka Moriwaki
Pages: 247-253
Published online: 10 Aug 2011
AbstractforA phase II study of rituximab combined with pirarubicin–cyclophosphamide, vincristine and prednisolone regimen as first-line therapy for patients with indolent B-cell lymphoma | Full Text | References | PDF (298.6 KB) | Supplemental
  • 284 Views
  • 2 CrossRef citations
  • 0Altmetric
Article
A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma
Anne W. Beaven, Thomas C. Shea, Dominic T. Moore, Tatyana Feldman, Anastasia Ivanova, Madlyn Ferraro, Peggy Ford, Judith Smith & Andre Goy
Pages: 254-258
Published online: 19 Sep 2011
AbstractforA phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma | Full Text | References | PDF (196.7 KB) | Supplemental
  • 367 Views
  • 25 CrossRef citations
  • 0Altmetric
Article
A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517
Mark H. Kirschbaum, Bryan H. Goldman, Jasmine M. Zain, James R. Cook, Lisa M. Rimsza, Stephen J. Forman & Richard I. Fisher
Pages: 259-262
Published online: 19 Sep 2011
AbstractforA phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517 | Full Text | References | PDF (184.6 KB) | Supplemental
  • 400 Views
  • 58 CrossRef citations
  • 0Altmetric
Article
Use of interim [18F]fluorodeoxyglucose-positron emission tomography is not justified in diffuse large B-cell lymphoma during first-line immunochemotherapy
M. Christina Cox, Vincenzo Ambrogi, Valerio Lanni, Elena Cavalieri, Sabrina Pelliccia, Francesco Scopinaro, Bruno Monarca, Paolo Marchetti & M. Antonietta Aloe Spiriti
Pages: 263-269
Published online: 23 Sep 2011
AbstractforUse of interim [18F]fluorodeoxyglucose-positron emission tomography is not justified in diffuse large B-cell lymphoma during first-line immunochemotherapy | Full Text | References | PDF (280.6 KB) | Supplemental
  • 339 Views
  • 20 CrossRef citations
  • 0Altmetric
Article
High prevalence of hepatitis B virus infection in multiple myeloma
Beihui Huang, Juan Li, Zhenhai Zhou, Dong Zheng, Junru Liu & Mei Chen
Pages: 270-274
Published online: 24 Oct 2011
AbstractforHigh prevalence of hepatitis B virus infection in multiple myeloma | Full Text | References | PDF (204.9 KB) | Supplemental
  • 592 Views
  • 18 CrossRef citations
  • 0Altmetric
Article
Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease
Heather Landau, Neeta Pandit-Taskar, Hani Hassoun, Adam Cohen, Alex Lesokhin, Nikoletta Lendvai, Pamela Drullinsky, Philip Schulman, Suresh Jhanwar, Elizabeth Hoover, Christina Bello, Elyn Riedel, Stephen D. Nimer & Raymond L. Comenzo
Pages: 275-281
Published online: 23 Sep 2011
AbstractforBortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease | Full Text | References | PDF (263.2 KB) | Supplemental
  • 713 Views
  • 12 CrossRef citations
  • 0Altmetric
Article
Survival of patients with hematological malignancy admitted to the intensive care unit: prognostic factors and outcome compared to unselected medical intensive care unit admissions, a parallel group study
Quentin A. Hill, Richard J. Kelly, Chetan Patalappa, Annika M. Whittle, Andrew J. Scally, Anthony Hughes, A. John Ashcroft & Anita Hill
Pages: 282-288
Published online: 29 Sep 2011
AbstractforSurvival of patients with hematological malignancy admitted to the intensive care unit: prognostic factors and outcome compared to unselected medical intensive care unit admissions, a parallel group study | Full Text | References | PDF (202.8 KB) | Supplemental
  • 449 Views
  • 28 CrossRef citations
  • 0Altmetric
Article
Clinicopathologic features and outcome of acute erythroid leukemia based on 2008 revised World Health Organization classification
Chia-Jen Liu, Ying-Chung Hong, Ching-Fen Yang, Shih-Hao Liu, Jyh-Pyng Gau, Jin-Hwang Liu, Liang-Tsai Hsiao, Chun-Yu Liu, Yuan-Bin Yu & Cheng-Hwai Tzeng
Pages: 289-294
Published online: 23 Sep 2011
AbstractforClinicopathologic features and outcome of acute erythroid leukemia based on 2008 revised World Health Organization classification | Full Text | References | PDF (236.3 KB) | Supplemental
  • 332 Views
  • 9 CrossRef citations
  • 0Altmetric
Article
A112, a tamibarotene dimethylaminoethyl ester, may inhibit human leukemia cell growth more potently than tamibarotene
Chao Yuan, Yu-Sheng Zhang, Yan-Na Cheng, Xia Xue, Wen-Fang Xu & Xian-Jun Qu
Pages: 295-304
Published online: 23 Sep 2011
AbstractforA112, a tamibarotene dimethylaminoethyl ester, may inhibit human leukemia cell growth more potently than tamibarotene | Full Text | References | PDF (645.5 KB) | Supplemental
  • 188 Views
  • 4 CrossRef citations
  • 0Altmetric
Article
Mechanisms regulating enhanced human leukocyte antigen class II-mediated CD4 + T cell recognition of human B-cell lymphoma by resveratrol
Faisal F. Y. Radwan, Lixia Zhang, Azim Hossain, Bently P. Doonan, Jason M. God & Azizul Haque
Pages: 305-314
Published online: 24 Oct 2011
AbstractforMechanisms regulating enhanced human leukocyte antigen class II-mediated CD4 + T cell recognition of human B-cell lymphoma by resveratrol | Full Text | References | PDF (648.4 KB) | Supplemental
  • 184 Views
  • 17 CrossRef citations
  • 0Altmetric
Article
Up-regulated autophagy by endogenous high mobility group box-1 promotes chemoresistance in leukemia cells
Liangchun Yang, Yan Yu, Rui Kang, Minghua Yang, Min Xie, Zhuo Wang, Daolin Tang, Mingyi Zhao, Liying Liu, Hong Zhang & Lizhi Cao
Pages: 315-322
Published online: 15 Nov 2011
AbstractforUp-regulated autophagy by endogenous high mobility group box-1 promotes chemoresistance in leukemia cells | Full Text | References | PDF (480.8 KB) | Supplemental
  • 636 Views
  • 58 CrossRef citations
  • 0Altmetric
Article
Genetic variability in N-acetyltransferase 2 gene determines susceptibility to childhood lymphoid or myeloid leukemia in Brazil
Crisiane Wais Zanrosso, Mariana Emerenciano, Alessandra Faro, Bruno Alves de Aguiar Gonçalves, Marcela Braga Mansur & Maria S. Pombo-de-Oliveira
Pages: 323-327
Published online: 25 Nov 2011
AbstractforGenetic variability in N-acetyltransferase 2 gene determines susceptibility to childhood lymphoid or myeloid leukemia in Brazil | Full Text | References | PDF (193.4 KB) | Supplemental
  • 159 Views
  • 13 CrossRef citations
  • 0Altmetric

Letters to the Editor

Letter
Breaking bad news in onco-hematology: new hope, new words?
Enrico Aitini
Pages: 328-329
Published online: 19 Sep 2011
CitationforBreaking bad news in onco-hematology: new hope, new words? | Full Text | References | PDF (128.3 KB) | Supplemental
  • 181 Views
  • 5 CrossRef citations
  • 0Altmetric

Letter

Letter
Induction treatment of light chain deposition disease with bortezomib: rapid hematological response with persistence of renal involvement
Jiri Minarik, Vlastimil Scudla, Tomas Tichy, Tomas Pika, Jaroslav Bacovsky, Pavel Lochman & Josef Zadrazil
Pages: 330-331
Published online: 24 Oct 2011
CitationforInduction treatment of light chain deposition disease with bortezomib: rapid hematological response with persistence of renal involvement | Full Text | References | PDF (137.9 KB) | Supplemental
  • 311 Views
  • 18 CrossRef citations
  • 0Altmetric
Letter
Lack of recurrence of imatinib-induced interstitial lung disease with nilotinib
Thomas Delomas, Christian Darné & Caroline Besson
Pages: 332-333
Published online: 19 Sep 2011
CitationforLack of recurrence of imatinib-induced interstitial lung disease with nilotinib | Full Text | References | PDF (159.8 KB) | Supplemental
  • 280 Views
  • 10 CrossRef citations
  • 0Altmetric
Letter
Reversible nicorandil induced perianal ulceration in acute myeloid leukemia
Faheem A. Ahmad & Mark W. Drummond
Pages: 334-335
Published online: 23 Sep 2011
CitationforReversible nicorandil induced perianal ulceration in acute myeloid leukemia | Full Text | References | PDF (127.8 KB) | Supplemental
  • 79 Views
  • 3 CrossRef citations
  • 0Altmetric
Letter
Monosomal karyotype routinely defines a poor prognosis subgroup in acute myeloid leukemia and is frequently associated with TP53 deletion
Jean-Baptiste Gaillard, Jean Chiesa, Dorothée Reboul, Anne Arnaud, Sophie Brun, Daniel Donadio, Carole Exbrayat, Stefan Wickenhauser, Pascal Bourquard, Eric Jourdan & Thierry Lavabre-Bertrand
Pages: 336-337
Published online: 19 Sep 2011
CitationforMonosomal karyotype routinely defines a poor prognosis subgroup in acute myeloid leukemia and is frequently associated with TP53 deletion | Full Text | References | PDF (143.2 KB) | Supplemental
  • 178 Views
  • 10 CrossRef citations
  • 0Altmetric
Letter
Prognosis of patients with t(8;16)(p11;p13) acute myeloid leukemia
Tanya Brown, John Swansbury & Mary M. Taj
Pages: 338-341
Published online: 23 Sep 2011
First Page PreviewforPrognosis of patients with t(8;16)(p11;p13) acute myeloid leukemia | Full Text | References | PDF (147.1 KB) | Supplemental
  • 273 Views
  • 15 CrossRef citations
  • 0Altmetric
Letter
Molecular cytogenetics studies reveal unexpected chromosomal inversion as variant of t(12;21)(p13;q22) in child with B-cell precursor acute lymphoblastic leukemia
Daniela R. Ney-Garcia, Thomas Liehr, Samarth Bhatt, Mariana T. de Souza, Roberto R. Capela de Matos, Renata Binato, Fernanda C. Jordy, Eliana Abdelhay, Raul C. Ribeiro & Maria Luiza M. Silva
Pages: 342-344
Published online: 29 Sep 2011
First Page PreviewforMolecular cytogenetics studies reveal unexpected chromosomal inversion as variant of t(12;21)(p13;q22) in child with B-cell precursor acute lymphoblastic leukemia | Full Text | References | PDF (178.7 KB) | Supplemental
  • 145 Views
  • 0 CrossRef citations
  • 0Altmetric
Letter
CD20 expression in angioimmunoblastic T cell lymphoma
Periklis G. Foukas, Maria Kefala, Sotirios Papageorgiou, Panagiotis Tsirigotis, Panayiotis Panayiotidis, Penelope Korkolopoulou, Aris Spathis, John Dervenoulas, Efstratios Patsouris, Petros Karakitsos & Ioannis G. Panayiotides
Pages: 345-347
Published online: 15 Nov 2011
First Page PreviewforCD20 expression in angioimmunoblastic T cell lymphoma | Full Text | References | PDF (343.6 KB) | Supplemental
  • 235 Views
  • 4 CrossRef citations
  • 0Altmetric

Explore articles

Explore the most recently published articles

High red cell mass and high plasma volume are independently associated with thrombotic risk in polycythemia vera
Ivan Krecak et al.
Letter to the Editor | Published online: 20 Jun 2024
Experience of using venetoclax in relapsed T- cell lymphoma
Jasmine Zain et al.
Letter to the Editor | Published online: 17 Jun 2024
Therapy-related myeloid neoplasms with single-hit TP53 mutations share the clinical, molecular, and survival characteristics of their multi-hit counterparts
Taylor Zak et al.
Article | Published online: 17 Jun 2024
Polycythemia vera: past, present and future
Ami B. Patel et al.
Review Article | Published online: 13 Jun 2024
View all latest articles